Stocks of Galectin Therapeutics Inc (NASDAQ:GALT) traded higher last session on Wall Street, up 32.17% to $1.15.
GALT stock price is now -51.60% away from the 50-day moving average and -56.13% away from the 200-day moving average. The market capitalization of the company currently stands at $94.70M.
With the price target enhanced from $9 to $12, H.C. Wainwright maintained Buy rating for Galectin Therapeutics Inc (NASDAQ: GALT). On February 13, 2019, B. Riley FBR recently initiated its ‘Buy’ rating on the stock quoting a target price of $11, while ‘H.C. Wainwright’ rates the stock as ‘Buy’
In other news, Jamil Khurram, Chief Medical Officer sold 13,654 shares of the company’s stock on Dec 23 ’24. The stock was sold for $12,044 at an average price of $0.88. Upon completion of the transaction, the Chief Medical Officer now directly owns 26,346 shares in the company, valued at $30297.9. An SEC document containing details of the transaction can be found on the SEC’s website. On Dec 23 ’24, President and CEO LEWIS JOEL sold 56,000 shares of the business’s stock. A total of $49,610 was realized by selling the stock at an average price of $0.89. This leaves the insider owning 897,012 shares of the company worth $1.03 million. A total of 30.30% of the company’s stock is owned by insiders.
During the past 12 months, Galectin Therapeutics Inc has had a low of $0.73 and a high of $4.27. The fifty day moving average price for GALT is $2.3768 and a two-hundred day moving average price translates $2.62195 for the stock.
The latest earnings results from Galectin Therapeutics Inc (NASDAQ: GALT) was released for 2024-06-30. The company reported revenue of $9.07 million for the quarter, compared to $9.17 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue fell -1.09 percent.
